SCHEMBL627650

SCHEMBL627650

c1ccc(Oc2ccc3c(NC4CC4)nc(-n4cccn4)nc3c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 14/20 0.67
ADORA2A P29274 3/20 0.49
DNMT3A Q9Y6K1 1/20 0.44
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
CCR4 P51679 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627346 0.95 EGLN1 (0.69) EGLN1ADORA2ADNMT3ACCR4
SCHEMBL627146 0.93 EGLN1 (0.67) EGLN1ADORA2ADNMT3ACCR4
SCHEMBL627243 0.86 EGLN1 (0.69) EGLN1ADORA2ADNMT3ACCR4
SCHEMBL622073 0.86 EGLN1 (0.67) EGLN1ADORA2ADNMT3ACCR4
SCHEMBL628374 0.85 EGLN1 (0.69) EGLN1ADORA2A
SCHEMBL626406 0.82 EGLN1 (0.70) EGLN1ADORA2A
SCHEMBL628188 0.82 EGLN1 (0.67) EGLN1MEN1KMT2A
SCHEMBL621686 0.81 EGLN1 (1.00) EGLN1
SCHEMBL4911813 0.79 ADORA2A (0.60) ADORA2AMEN1KMT2ACCR4
SCHEMBL626953 0.78 EGLN1 (0.69) EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-04-02 US disclosed
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-31 US disclosed
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9573940-B2 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-16 US disclosed
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARAMCEUTICA NV (BE) 2014-10-16 US disclosed
US-8796263-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-08-05 US disclosed
EP-2603502-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-06-19 EP disclosed
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-06-06 US disclosed
WO-2012021830-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885DNMT3A 926/4885
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885DNMT3A 926/4885
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885DNMT3A 1469/4885
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3619/4885DNMT3A 1041/4885
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885DNMT3A 926/4885
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885DNMT3A 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.